Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simplified vs Divided-Dose Tranexamic Acid in Traumatic Hemorrhagic Shock
NCT07869537Phase 4Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Oct 2026
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tranexamic acid in Traumatic hemorrhagic shock (THS), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Incidence of thrombotic events. Started Oct 2026; status: recruiting.
02
Drugs
tranexamic acid
03
Conditions
Traumatic hemorrhagic shock (THS)
Beyond the preview
Go deeper on NCT07869537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07869537.